Effect of some newly synthesized xanthone and piperazine derivatives with cardiovascular activity on rheology of human erythrocytes in vitro

• Published in: Clinical hemorheology and microcirculation Vol. 67; no. 1; pp. 1 - 14
• Main Authors: Kózka, Mariusz, Słoczyńska, Karolina, Szkaradek, Natalia, Waszkielewicz, Anna M., Pękala, Elżbieta, Marona, Henryk
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2017
• Subjects: Acetylcholinesterase - metabolism; Cardiovascular Physiological Phenomena - drug effects; Erythrocyte Aggregation; Erythrocytes - metabolism; Humans; Male; Piperazines - chemical synthesis; Piperazines - chemistry; Rheology - methods; Xanthones - chemical synthesis; Xanthones - chemistry; red blood cells; Erythrocyte aggregation; erythrocyte deformability; piperazine derivatives; xanthones
• ISSN: 1386-0291; 1875-8622; 1875-8622
• DOI: 10.3233/CH-16001A

This in vitro study was designed to examine the effect of some newly synthesized aminoalcanolic derivatives of xanthone (I, II) and aroxyalkyl derivatives of 2-methoxyphenylpiperazine (III, IV) having cardiovascular activity on the haemorheological parameters of RBCs from healthy individuals and patients with chronic venous disease. Additionally, the influence of compounds I-IV on some RBCs associated enzymes such as acetylcholinesterase (Ache), glucose-6-phosphate dehydrogenase (G6PD) and glutathione reductase (GR) as well as glutathione (GSH) content were determined in vitro in RBCs from healthy subjects. The study showed that compounds I, III and IV significantly increased RBCs deformability. Moreover, both xanthone derivatives reduced RBCs aggregation and diminished RBCs aggregates strength in all RBCs groups. Compounds II and III significantly improved Ache activity, whereas compounds I and II increased G6PD and GR activity and GSH level. In conclusion, compounds I, III and IV, which significantly improved RBCs deformability in vitro, may facilitate the passage of blood in the vascular system. Additionally, compounds I and II which inhibit RBCs aggregates formation in vitro may contribute to more rapid degradation of red blood cell aggregates in circulating blood.